c-MET (R970C)

MET · Variant type: point · HGVS: p.R970C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Capmatinib	95.5%	4.5%	99.75
2	Tepotinib	93.8%	6.2%	99.75
3	Gilteritinib	92.1%	7.9%	88.97
4	Deucravacitinib	86.4%	13.6%	98.99
5	Pacritinib	73.8%	26.2%	88.64
6	Tivozanib	71.0%	29.0%	92.42
7	Erdafitinib	62.4%	37.6%	95.71
8	Repotrectinib	57.5%	42.5%	84.21
9	Defactinib	57.4%	42.6%	92.68
10	Canertinib	48.7%	51.3%	96.49
11	Abemaciclib	40.5%	59.5%	91.48
12	Neratinib	38.0%	62.0%	93.18
13	Selpercatinib	34.6%	65.4%	96.72
14	Sunitinib	31.9%	68.1%	91.73
15	Fedratinib	27.5%	72.5%	96.21
16	Vandetanib	19.6%	80.4%	95.74
17	Entrectinib	19.0%	81.0%	93.69
18	Avapritinib	16.7%	83.3%	97.73
19	Pralsetinib	15.9%	84.1%	93.43
20	Erlotinib	15.6%	84.4%	99.75
21	Lazertinib	15.1%	84.9%	97.47
22	Gedatolisib	11.9%	88.1%	99.75
23	Pirtobrutinib	10.6%	89.4%	99.49
24	Zanubrutinib	10.3%	89.7%	98.24
25	Pexidartinib	9.4%	90.6%	99.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Capmatinib	95.5%	—	—
Tepotinib	93.8%	—	—
Gilteritinib	92.1%	—	—
Deucravacitinib	86.4%	—	—
Pacritinib	73.8%	—	—
Tivozanib	71.0%	—	—
Erdafitinib	62.4%	—	—
Repotrectinib	57.5%	—	—
Defactinib	57.4%	—	—
Canertinib	48.7%	—	—
Abemaciclib	40.5%	—	—
Neratinib	38.0%	—	—
Selpercatinib	34.6%	—	—
Sunitinib	31.9%	—	—
Fedratinib	27.5%	—	—
Vandetanib	19.6%	—	—
Entrectinib	19.0%	—	—
Avapritinib	16.7%	—	—
Pralsetinib	15.9%	—	—
Erlotinib	15.6%	—	—
Lazertinib	15.1%	—	—
Gedatolisib	11.9%	—	—
Pirtobrutinib	10.6%	—	—
Zanubrutinib	10.3%	—	—
Pexidartinib	9.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms